Literature DB >> 18001849

GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation.

Nicolas Delcourt1, Joël Bockaert, Philippe Marin.   

Abstract

A large body of evidence indicates that agonists of some G protein-coupled receptors (GPCRs) can activate growth factor receptor tyrosine kinases (RTKs) in the absence of added growth factor. This phenomenon, called transactivation, is an important pathway that contributes to growth-promoting activity of many GPCR ligands. Reciprocally, recent advances indicate that RTKs utilize GPCR signalling molecules to transduce signals and that RTK ligands themselves can transactivate GPCRs. This novel transactivation process, which places GPCR signalling downstream of RTKs, either requires the production of a GPCR ligand of the transactivated GPCR or occurs in a ligand independent manner within an integrated signalling network. Here, we provide an overview of the molecular mechanisms involved in this novel cross-communication between GPCRs and RTKs and discuss its relevance in the specification of growth factor signalling and functions.

Mesh:

Substances:

Year:  2007        PMID: 18001849     DOI: 10.1016/j.tips.2007.09.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  75 in total

1.  ERK and β-arrestin interaction: a converging point of signaling pathways for multiple types of cell surface receptors.

Authors:  Haifeng Eishingdrelo; Wei Sun; Hua Li; Li Wang; Alex Eishingdrelo; Sheng Dai; John C McKew; Wei Zheng
Journal:  J Biomol Screen       Date:  2014-10-31

Review 2.  Heterotrimeric G protein signaling outside the realm of seven transmembrane domain receptors.

Authors:  Caroline Marty; Richard D Ye
Journal:  Mol Pharmacol       Date:  2010-04-19       Impact factor: 4.436

3.  Two insulin-like peptide family members from the mosquito Aedes aegypti exhibit differential biological and receptor binding activities.

Authors:  Zhimou Wen; Monika Gulia; Kevin D Clark; Animesh Dhara; Joe W Crim; Michael R Strand; Mark R Brown
Journal:  Mol Cell Endocrinol       Date:  2010-07-17       Impact factor: 4.102

Review 4.  Regulation of Long Bone Growth in Vertebrates; It Is Time to Catch Up.

Authors:  Alberto Roselló-Díez; Alexandra L Joyner
Journal:  Endocr Rev       Date:  2015-10-20       Impact factor: 19.871

Review 5.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

6.  Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.

Authors:  Sarah J Morgan; Susanne Neumann; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

Review 7.  TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

Authors:  Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Pharmacol Ther       Date:  2020-02-13       Impact factor: 12.310

8.  Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Authors:  Christine C Krieger; Susanne Neumann; Robert F Place; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2014-12-08       Impact factor: 5.958

9.  Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.

Authors:  Cecilea C Clayton; Michael R Bruchas; Michael L Lee; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2009-12-03       Impact factor: 4.436

10.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.